



05-01-02

Page 1 of 2

0360

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/067,125	02/04/2002	Brenda F. Baker	ISPH-0628

CONFIRMATION NO. 7371

FORMALITIES LETTER

OC000000007554199

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, NJ 08053

Date Mailed: 02/28/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ISPH-0628

Inventors: Baker et al.

Serial No.: 10/067,125

Filing Date: February 4, 2002

Examiner: Not yet assigned

Group Art Unit: 1635

Title: Antisense Modulation of Expression of
Tumor Necrosis Receptor-Associated
Factors (TRAFs)

"Express Mail" Label No. EV104364729US
Date of Deposit - April 29, 2002

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the U.S. Patent and
Trademark Office, Box Sequence, P.O. Box 2327
Arlington, VA 22202

By Kathleen A. Tyrrell
Typed Name: Kathleen A. Tyrrell

Assistant Commissioner for Patents
BOX Sequence
United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

RESPONSE TO NOTICE TO COMPLY

In response to the "Notice to Comply" dated February 28,
2002, a response to which is due April 28, 2002, enclosed
herewith is:

(XX) Amendment under 1.825;



- (X) Statement to Support Filing and Submission in accordance with 37 CFR §§1.821 through 1.825;
- (XX) Paper Copy of the Sequence Listing;
- () Substitute copy of the computer readable form of Sequence Listing;
- (XX) Copy of Notice to Comply;
- () Petition for Three (3) Month Extension of Time;
- (XX) Other: Request under 37 C.F.R. 1.821(e).

The Commissioner is hereby authorized to charge any underpayment associated with this communication or credit any overpayment to Deposit Account No. 50-1619. This sheet is attached in duplicate.

Respectfully submitted,

Kathleen A. Tyrrell
Kathleen A. Tyrrell
Registration No. 38,350

Date: April 29, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515